Administration of the FGF-19 analog NGM282 reduces atherosclerosis in Apoe−/− mice, enhances plasma HDL-cholesterol in healthy subjects (444), and improved NASH and fibrosis in phase II clinical trials (445). This evidence concerns the gene FGF19 and metabolic dysfunction-associated steatohepatitis.